Sirtuins In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Sirtuins In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications. [1]
Sirtuins are a family of NAD+-dependent deacetylases that regulate cellular metabolism, stress response, and longevity. SIRT1 and SIRT2 are the most studied sirtuins in the nervous system, with well-documented roles in neurodegeneration. [2]
| Sirtuin | Location | Primary Function | Neurodegeneration Role | [3]
|---------|----------|------------------|----------------------| [4]
| SIRT1 | Nucleus/cytoplasm | Deacetylase, metabolism | Neuroprotection |
| SIRT2 | Cytoplasm | Tubulin deacetylation | Mitochondrial function |
| SIRT3 | Mitochondria | Stress response | Antioxidant |
| SIRT4 | Mitochondria | Metabolism | Insufficiently characterized |
| SIRT5 | Mitochondria | Urea cycle | Insufficiently characterized |
| SIRT6 | Nucleus | DNA repair | Insufficiently characterized |
| SIRT7 | Nucleolus | Ribosome biogenesis | Insufficiently characterized |
SIRT1 is a NAD+-dependent deacetylase that:
| Approach | Mechanism | Status |
|---|---|---|
| Resveratrol | SIRT1 activator | Clinical trials |
| SRT2104 | Synthetic SIRT1 agonist | Phase I |
| NAD+ precursors | Boost SIRT1 substrate | Investigational |
SIRT1 protects dopaminergic neurons through:
SIRT1 modulates Huntington's disease pathology:
SIRT2 is primarily a cytoplasmic sirtuin:
The interplay between SIRT1 and SIRT2 is critical:
NAD+ is the essential cofactor for sirtuin activity:
| Precursor | Mechanism | Clinical Status |
|---|---|---|
| Nicotinamide riboside (NR) | NAD+ precursor | Clinical trials |
| Nicotinamide mononucleotide (NMN) | NAD+ precursor | Phase I/II |
| Nicotinamide (NAM) | NAD+ precursor | Approved |
| Drug | Target | Indication | Status |
|---|---|---|---|
| Resveratrol | SIRT1 | AD, PD | Phase II |
| SRT2104 | SIRT1 | AD | Phase I |
| SRT3024 | SIRT1 | PD | Preclinical |
| EX-527 | SIRT2 | PD | Research |
The study of Sirtuins In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Gao et al. SIRT1 and Alzheimer's disease (2022). 2022. ↩︎
Liu et al. SIRT2 in Parkinson's disease (2019). 2019. ↩︎
Jiang et al. NAD+ metabolism in neurodegeneration (2021). 2021. ↩︎
Wu et al. Resveratrol and neurodegeneration (2023). 2023. ↩︎